B Cell Depletion: On the Rise

Journal of Pediatrics

Volumn 150, Issue 4, 2007, Pages 335-337

  Hinze, Claas H ^a   Grom, Alexei A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BRONCHOSPASM; CELL THERAPY; CHILL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FEVER; FLUSHING; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INJECTION SITE REACTION; LYMPHOCYTE DEPLETION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; RASH; REPEAT PROCEDURE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TOXICITY; URTICARIA;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHILD; DRUG EVALUATION; DRUG MONITORING; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME;

EID: 33947282716     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.12.050     Document Type: Editorial

References (17)

1. El-Hallak M., Binstadt B.A., Leichtner A.M., Bennett C.M., Neufeld E.J., Fuhlbrigge R.C., et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 150 (2007) 376-382
2. http://www.ClinicalTrials.gov. (search for Rituximab)
3. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15 (1994) 450-454
4. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590
5. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
6. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 613-620
7. Ng K.P., Leandro M.J., Edwards J.C., Ehrenstein M.R., Cambridge G., and Isenberg D.A. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 65 (2006) 942-945
8. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31 (2005) 456-473
9. Edwards J.C., Cambridge G., and Leandro M.J. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 20 (2006) 915-928
10. Larrar S., Guitton C., Willems M., and Bader-Meunier B. Severe hematological side effects following rituximab therapy in children. Haematologica 91 8 Suppl (2006) ECR36
11. Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 (2006) 2639-2642
12. Friedrichs B., Tiemann M., Salwender H., Verpoort K., Wenger M.K., and Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91 (2006) 1426-1427
13. Kalled S.L. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204 (2005) 43-54
14. Becker-Merok A., Nikolaisen C., and Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15 (2006) 570-576
15. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., and Mariette X. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis (2006) [Epub ahead of print]
16. Vallerskog T., Heimburger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8 (2006) R167
17. Ding C., and Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 7 (2006) 464-472